Harpoon Therapeutics (NASDAQ:HARP) Stock Rating Reaffirmed by Oppenheimer

Harpoon Therapeutics (NASDAQ:HARP)‘s stock had its “outperform” rating reissued by analysts at Oppenheimer in a report issued on Tuesday, Benzinga reports.

A number of other equities analysts have also issued reports on HARP. Citigroup reaffirmed a “neutral” rating and issued a $23.00 target price (up from $13.00) on shares of Harpoon Therapeutics in a research report on Monday, February 26th. TD Cowen restated a “market perform” rating on shares of Harpoon Therapeutics in a research note on Tuesday, January 16th. HC Wainwright cut Harpoon Therapeutics from a “buy” rating to a “neutral” rating and upped their price objective for the company from $12.00 to $23.00 in a research note on Monday, January 8th. Finally, Leerink Partnrs downgraded Harpoon Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, January 8th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $27.25.

Harpoon Therapeutics Stock Up 0.1 %

Shares of HARP opened at $23.01 on Tuesday. The firm has a market cap of $389.61 million, a PE ratio of -2.63 and a beta of 2.11. The company’s fifty day moving average is $22.70 and its two-hundred day moving average is $13.72. Harpoon Therapeutics has a fifty-two week low of $3.11 and a fifty-two week high of $23.21.

Insider Activity

In other news, major shareholder Merck & Co., Inc. acquired 21,397,205 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was acquired at an average price of $23.00 per share, for a total transaction of $492,135,715.00. Following the completion of the acquisition, the insider now directly owns 1,000 shares in the company, valued at approximately $23,000. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 17.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Sequoia Financial Advisors LLC acquired a new position in shares of Harpoon Therapeutics in the 1st quarter worth $66,000. Delphia USA Inc. purchased a new position in Harpoon Therapeutics in the 1st quarter worth about $57,000. Two Sigma Investments LP purchased a new position in Harpoon Therapeutics in the 1st quarter worth about $42,000. Susquehanna International Group LLP lifted its stake in Harpoon Therapeutics by 168.1% during the first quarter. Susquehanna International Group LLP now owns 53,949 shares of the company’s stock valued at $40,000 after buying an additional 33,830 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in shares of Harpoon Therapeutics in the first quarter worth about $32,000. Institutional investors own 74.01% of the company’s stock.

About Harpoon Therapeutics

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma.